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Pituitary tumors develop in about one-quarter of the population, and most arise from the anterior lobe (AL). The pituitary gland
is particularly sensitive to genetic alteration of genes involved in the cyclin-dependent kinase (CDK) inhibitor (CKI)–CDK-reti-
noblastoma protein (Rb) pathway. Mice heterozygous for the Rb mutation develop pituitary tumors, with about 20% arising
from the AL. Perplexingly, none of the CKI-deficient mice reported thus far develop pituitary AL tumors. In this study, we show
that deletion of p19Ink4d (p19), a CKI gene, in mice results in spontaneous development of tumors in multiple organs and tissues.
Specifically, more than one-half of the mutant mice developed pituitary hyperplasia or tumors predominantly in the AL. Tumor
development is associated with increased cell proliferation and enhanced activity of Cdk4 and Cdk6 and phosphorylation of Rb
protein. Though Cdk4 is indispensable for postnatal pituitary cell proliferation, it is not required for the hyperproliferative pitu-
itary phenotype caused by p19 loss. Loss of p19 phosphorylates Rb in Cdk4/ pituitary AL cells and mouse embryonic fibro-
blasts (MEFs) and rescues their proliferation defects, at least partially, through the activation of Cdk6. These results provide the
first genetic evidence that p19 is a tumor suppressor and the major CKI gene that controls pituitary AL cell proliferation.
The retinoblastoma protein (Rb) family includes three structur-ally related nuclear phosphoproteins, pRB, p107, and p130,
which when hypophosphorylated, negatively regulate the activity
of E2F transcription factors to prevent S-phase entry. In mamma-
lian cells, extracellular mitogens induce the expression of D-type
cyclins and consequently activate cyclin D and cyclin-dependent
kinase 4/6 (CDK4/6) binding, leading to phosphorylation and
functional inactivation of Rb proteins. Conversely, inhibition of
CDK4/6, resulting from either lack of cyclin D synthesis or bind-
ing with CDK inhibitors (CKIs), retains Rb proteins in their
growth-suppressive states and prevents G1-to-S transition. Dis-
ruption of this CKI/cyclin D-CDK4/6-pRB/E2F pathway acceler-
ates G1 cell cycle progression and leads to cancer development
(1–3). In fact, Rb is frequently mutated and cyclin D and CDK4/6
are frequently amplified or overexpressed in human tumors (1–3),
and consistently, mutations inactivating Rb (4–7) result in the
development of various tumor types in mice.
Mammalian cells express two distinct families of CKIs, the p21
family, including p21Cip1/Waf1, p27Kip1 and p57Kip2 (here p21, p27,
p57), and the INK4 family comprising p16Ink4a, p15Ink4b, p18Ink4c,
and p19Ink4d (here p16, p15, p18, and p19). Biochemically, CKIs
within each family act almost indistinguishably in binding to and
regulating CDK enzymes but differ among the families. The p21
family proteins are capable of interacting with multiple CDK-
cyclin complexes, whereas the INK4 proteins exclusively bind to
and inhibit the kinase activity of CDK4 and CDK6 (1–3). The
physiologic significance of evolving a separate family of CKIs and
multiple members within each family is presumed to meet the
increasing needs for integrating more-intricate and multifaceted
cell growth signals into a single cell cycle control machinery. Sup-
porting this notion are the observations that the expression of
individual CKI genes is activated selectively by different check-
point pathways and maintained differentially in discrete adult and
senescent tissues. In addition, distinct temporary and spatial pat-
terns are displayed during both in vitro cell differentiation and in
vivo embryonic development (1). Further support for different
physiologic functions of individual CKI genes in vivo is derived
from the genetic analyses of mutant strains of mice with targeted
mutation of individual CKI genes. Various phenotypes were ob-
served in these mice, including compromised DNA damage re-
sponse after inactivation of the p21 gene (8, 9), increase of tumor
development resulting from loss of function of p16 and p15 (10–
12), severe developmental defects after p57 mutation (13), and
widespread hyperplastic cell proliferation and organomegaly in
p18 and p27 null mice (11, 14–17).
The four INK4 proteins are biochemically very similar, if not
indistinguishable (1, 2). Though p19 interacts preferentially with
Cdk4 in testis (18) and p18 has greater affinity for CDK6 (1, 2),
side-by-side comparisons of complex formation between ectopi-
cally overexpressed INK4 with endogenous CDK4 and CDK6
demonstrated a similar affinity of individual INK4 proteins in
binding to CDK4 and CDK6 (19). It seems that the differences in
the various INK4-CDK interactions are subtle, if not inconse-
quential, and might have been caused by the analysis of cell types
with different endogenous levels of CDK4 and CDK6 (1). The
existence of a linear INK4-CDK4/6-Rb-G1 control pathway in
mammalian cells in vivo is supported by our previous findings that
inactivation of either p16 or p18 in mice results in elevated Cdk4
kinase activity and Rb phosphorylation and that the function of
p18 in mice is wholly dependent on Cdk4 (20–22).
p16 is frequently mutated in human tumors (23), and muta-
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tions inactivating p16 (10, 12), p15 (11), or p18 (11, 15) in mice
lead to tumor development, indicating that p16, p15, and p18 are
tumor suppressors. p19 is highly and ubiquitously expressed in
both fetal and adult tissues (24), and loss or downregulation of
p19 is frequently detected in human hepatocellular carcinoma
(25), testicular germ cell tumors (26), glioblastoma, leukemia, and
lung adenocarcinoma (Oncomine TCGA data set; https://www
.oncomine.org/resource/). Paradoxically, disruption of p19 in
mice by insertion of a LacZ-Neo cassette into exon 2 results in a
relatively minor phenotype of testicular atrophy with no tumor
development (27, 28).
The pituitary gland is a central endocrine organ that controls
growth, reproduction, and metabolism. Autopsy studies suggest
that pituitary tumors develop in about one-quarter of the popu-
lation, and most are pituitary anterior lobe (AL) tumors that ex-
press and secrete various hormones that contribute to multiple
endocrine syndromes (29). The pituitary gland is highly sensitive
to genetic alteration of genes in the CKI-CDK-Rb pathway. Pro-
teins involved in regulation of this pathway are altered in nearly all
human pituitary tumors (30–35), and Cdk4 is indispensable for
postnatal proliferation of the anterior pituitary in mice (36–38).
Mice heterozygous for the Rb mutation or chimeric for homozy-
gous inactivation of Rb are highly predisposed to pituitary tumors
(4–7), most of which are in the intermediate lobe (IL). About 20%
of Rb heterozygous mice develop pituitary AL tumors (6, 34).
Interestingly, loss of p27 (14, 16, 17) or p18 (11, 15) in mice leads
to pituitary tumor formation predominantly in the IL, and muta-
tions conferring Cdk4 resistance to Ink4 result in the development
of pituitary tumors mostly in the AL (39). Perplexingly, none of
the CKI-deficient mice reported thus far developed pituitary AL
tumors (1, 2, 34). Since p19 is predominantly expressed in the AL
of the pituitary (40), we hypothesized a function of p19 in con-
trolling pituitary AL cell proliferation.
In this study, we generated p19 knockout mice by deletion of
the p19 gene from the genome. Our analysis of p19-deficient mice
suggests that p19 is a tumor suppressor and the major CKI gene
that controls pituitary AL cell proliferation.
MATERIALS AND METHODS
Gene targeting and generation of mutant mice. The targeting construct
was generated to delete a 4.6-kb genomic fragment containing both exons
1 and 2 encoding all 166 amino acid residues of the mouse p19 protein.
Briefly, a 16.4-kb mouse genomic DNA fragment spanning the p19 locus
was isolated by PCR from mouse embryonic stem (ES) cell genomic DNA.
A LoxP site was introduced downstream of exon 2 by site-directed mu-
tagenesis (Stratagene), and a neomycin (neo) resistance gene flanked by
LoxP sites was inserted upstream of the promoter region. The linearized
targeting construct was electroporated into embryonic day 14 (E14) ES
cells that were selected with G418 and ganciclovir. Doubly resistant
p19/NeoFlox clones were screened for homologous recombination events
and confirmed by PCR and Southern blot analysis. After transfection of
Cre recombinase, p19/ ES clones with deletion of the neo cassette and
exons 1 and 2 were screened and identified. Three independent p19/ ES
clones were injected into C57BL/6 blastocysts, and chimeric mice were
crossed with C57BL/6 mice to generate p19/ heterozygotes. p19/
mice were backcrossed for six generations with C57BL/6 mice before be-
ing used for this study. p19/ mice were intercrossed to generate p19/
mice, and successful deletion of p19 was confirmed by PCR and Southern
blotting. p19 deficiency was further confirmed by Western blotting.
The generation of Cdk4, p18, and p18; Cdk4 mutant mice has been
described previously (15, 21, 38). Mice deficient for p19 were bred to the
mice heterozygous for Cdk4 to create double-heterozygous mice, which
were then intercrossed to generate p19; Cdk4 double-knockout mice. An-
imals were genotyped by PCR and monitored as described previously (15,
21, 38). Cohorts were housed and analyzed in a common setting, and
littermate controls were used for all experiments as indicated. All animal
studies were approved by the Institutional Animal Care and Use Commit-
tee (IACUC) at the University of North Carolina and at the University of
Miami.
Analysis of fertility and diabetes. Two- to four-month-old p19/,
Cdk4/, p19/; Cdk4/, or wild-type (WT) C57BL/6 male and female
mice were individually housed for 21 days with a paired female or male
mouse of a similar age. Females were then separated from the males and
allowed to rest for 21 days. A female was considered fertile if she gave birth
to pups, and a male was fertile if the female in the same cage gave birth to
pups. Litter size was determined by counting pups. Blood glucose levels
were monitored in the morning (8 to 10 a.m.) by using an automatic
glucose monitor (Glucometer Elite; Bayer). Each mouse was analyzed
twice for blood glucose on two consecutive days.
Tumor analysis, histopathology, and IHC. For the determination of
spontaneous tumor incidence, WT and p19 mutant mice with visible tu-
mors, exhibiting morbidity, weight loss, or paralysis were sacrificed. The
remaining surviving mice were sacrificed at 27 months of age. A full au-
topsy was performed, and tissues were fixed and histologically examined
by two pathologists after hematoxylin and eosin (H&E) staining. The
survival rate was calculated by the Kaplan-Meier method with Prism soft-
ware (version 5.01; GraphPad Software), and statistical significance was
assessed with Wilcoxon’s log rank test. Histopathology and immunohis-
tochemistry (IHC) were performed as described previously (21). Primary
antibodies used were as follows: p-Rb-S608 (Cell Signaling); prolactin
(PRL), growth hormone (GH), and follicle-stimulating hormone (FSH)
(Thermo Scientific); Cdk6 (generated and characterized in the lab [41]);
and Ki67 (Novartis). Immunocomplexes were detected using the Vec-
tastain Elite ABC peroxidase kit (Vector Laboratories).
MEFs and flow cytometry procedures. Primary MEFs were isolated
from E13.5 embryos. Early-passage MEFs (passage 4) from individual
embryos were plated in 100-mm plates and incubated in Dulbecco’s mod-
ified Eagle medium (DMEM) plus 10% fetal bovine serum (FBS). For
serum starvation, asynchronous cultures at approximately 50% conflu-
ence were washed with phosphate-buffered saline (PBS) and serum
starved in DMEM containing 0.1% FBS for 72 h. Cells were restimulated
by addition of DMEM with 10% FBS. For bromodeoxyuridine (BrdU)
labeling, MEFs were grown in media with or without serum containing 10
M BrdU for 1 h. Nuclei were isolated following trypsinization and fixa-
tion with 95% ethanol by incubation in 0.08% pepsin (Sigma) in 0.1 N
HCl for 20 min at 37°C. Nuclear DNA was denatured by incubating in 2 N
HCl for 20 min at 37°C followed by neutralization with Na2B4O7, pH 8.5.
Incorporated BrdU was detected using anti-BrdU-fluorescein isothiocya-
nate (FITC) (1:10 dilution; Becton, Dickinson) in 10 mM HEPES (pH
7.3), 150 mM NaCl, 4% FBS, and 0.5% Tween 20. MEFs were then har-
vested and resuspended in PBS containing 1% FBS, incubated with pro-
pidium iodide (PI; 5 g/ml1), and RNase A (0.1 mg/ml1) for 30 min at
37°C. The samples were analyzed with a FACScan or LSRFortessa (Becton,
Dickinson), and the data were processed with Summit (version 3.0; BD
Biosciences) and Kaluza (version 1.2; Beckman Coulter) software.
RNA interference (RNAi). A pair of complementary small interfering
RNA (siRNA) oligonucleotides targeting nucleotides 209 to 229 (AAGA
UGCCUCCGGUACUAGUC) relative to the translation initiation codon
of mouse p19 were synthesized at Dharmacon (Lafayette, CO). Early-
passage wild-type MEF cells (passage 3) were seeded at 20 to 30% con-
flunency in a 60-mm plate and transfected twice with siRNA at 24 and 48
h after initial seeding with either single-sense strand siRNA oligonucleo-
tide or annealed siRNA duplex. A 120-l volume of Opti-MEM was
mixed with 30 l Oligofectamine reagent for 8 min and incubated with a
mixture containing 30 l siRNA and 500 l Opti-MEM for 20 min at
room temperature. An additional 320 l of Opti-MEM was added to the
mixture, and the entire 1,000 l was added for transfection into each
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60-mm plate. Twenty-four hours after the second transfection, RNA or
protein was harvested for further analysis.
qRT-PCR. Total RNA was extracted using the RNeasy minikit (Qia-
gen), and cDNA was synthesized with random hexamers by the Super-
Script III first-strand synthesis system (Invitrogen). The cDNA was added
to a quantitative reverse transcription-PCR (qRT-PCR) mixture that con-
tained 1 SYBR green PCR master mix (Applied Biosystems) and 70 nM
gene-specific primers. Assays were performed in triplicate on a CFX96
real-time PCR detection system (Bio-Rad). The expression level of each
gene was normalized with GAPDH (glyceraldehyde-3-phosphate dehy-
drogenase). The specific PCR primer sequences are available upon re-
quest.
Immunoprecipitation and Western, Southern, and Northern blots.
Tissue or MEF lysates were prepared as previously reported (15, 21).
Antibodies to Rb (BD Pharmingen), p19, and tubulin (Santa Cruz), as
well as horseradish peroxidase (HRP)-protein A (Invitrogen) were
purchased commercially. Antibodies to Cdk4, Cdk6, and cyclins D1,
D2, and D3 (Cyc D1, D2, and D3) were described previously (41–43).
The procedures for immunoprecipitation and Western and Southern
blotting were performed as described previously (41, 43, 44). For
Northern blot analysis, MEF cells at early passage were serum deprived
(0.1% FBS) for 3 days and released from quiescence by serum stimu-
lation (10% FBS). Total RNA was prepared from cells at different time
points after serum stimulation as well as from an asynchronized cell
population as indicated. RNA samples were resolved on a 1% agarose
gel, transferred to a nitrocellulose filter, and hybridized with a probe
derived from full-length mouse p19 cDNA. The blot was then stripped
and rehybridized with a mouse Gapdh probe.
Kinase assay. Kinase assays were performed using the ADP-Glo kinase
assay kit (Promega). Protein lysate from MEFs or pituitary tissues pooled
from three mice of the same genotype at 1 year of age was immunopre-
cipitated with 1 g of Cdk4 and Cdk6 antibodies, and rabbit IgG was used
as the control. After overnight incubation, protein A/G-agarose beads
(Santa Cruz) were added, incubated for 1 h, and washed three times with
lysis buffer followed by two washes in kinase reaction buffer (50 mM
HEPES, 10 mM MgCl2, 5 mM MnCl2, 10 M ATP, and 1 mM dithiothre-
itol [DTT]) (45). Beads were then resuspended in 10 l kinase reaction
buffer and incubated for 1 h at 30°C with glutathione S-transferase
(GST)–Rb (45). The reaction was terminated by adding 5 l ADP-Glo
reagent, and the mixture was incubated for 40 min at room temperature
followed by addition of 10 l kinase detection reagent and incubation at
room temperature for 30 min. Luminescence was determined using a
20/20n luminometer (Turner Biosystems). Alternatively, for detection of
kinase activity by Western blotting, Laemmli sample buffer was added to
the completed kinase reaction mixture and a phosphothreonine-specific
antibody (Cell Signaling) was used to detect phosphorylated Rb.
RESULTS
Targeted deletion of the mouse p19 gene. We deleted the mouse
p19 gene by targeted homologous recombination. We made a tar-
geting construct in which a 4.6-kb genomic fragment containing
both exons 1 and 2 that encodes the full-length p19 protein was
flanked by LoxP sites (Fig. 1A). The linearized targeting construct
was electroporated into ES cells, and G418 and ganciclovir doubly
resistant clones were screened for homologous recombination by
Southern blotting and PCR (Fig. 1B). Targeted p19/NeoFlox ES
cells were transfected with an expression vector encoding Cre re-
FIG 1 Targeted deletion of p19 locus. (A) Schematic presentation of the
mouse p19 locus. A 16.4-kb fragment of mouse genomic DNA, spanning both
exons, was amplified by PCR from mouse ES cell genomic DNA and verified by
DNA sequencing. LoxP sites were inserted at the indicated sites. (B) After
electroporation into E14 ES cells, G418 and ganciclovir doubly resistant clones
were screened for homologous recombination by PCR and Southern blotting.
Re, recombined allele. (C) Targeted p19/NeoFlox ES cells were transfected with
cytomegalovirus (CMV)-Cre vector. Deletion of NEO and exons 1 and 2
(p19/) was screened by Southern blotting. Three independent p19/ ES
clones were injected into C57BL/6 blastocysts. Germ line-transmitted agouti
pups were intercrossed, and the genomic DNA from the progeny ears was
analyzed by Southern blotting. (D) p19 deficiency was confirmed by Western
blotting of protein lysates from E16 embryos and MEFs of the indicated geno-
type. (E) Schematic map of genomic structure of mouse chromosome 9 span-
ning the p19 locus. A 22.75-kb region on mouse chromosome 9 spanning the
p19 locus is shown based on the assembly by NCBI. Three genes are identified
in this region. (F) The expression of genes neighboring the p19 locus was
examined by qRT-PCR. RNA from asynchronously growing MEFs was ex-
tracted and analyzed for the expression of the genes indicated. Real-time am-
plification curves for Kri1, p19, and Ap1m2 from cDNA of WT and p19/
MEFs are shown (left). Results represent the means  standard deviations
(SD) from triplicates of each of the three independent MEF lines (right). Ex-
pression of p19 was not detected, and that of Kri1 and Ap1m2 was unchanged
in p19/ MEFs. RFU, relative fluorescence units.
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combinase, and p19/ ES clones that had neo and exons 1 and 2
removed were screened and isolated by PCR and Southern blot-
ting. Three independent p19/ ES clones were injected into blas-
tocysts to generate mutant mice (Fig. 1C and data not shown).
Offspring from three independent ES lines were later shown to be
phenotypically indistinguishable. p19 deficiency was confirmed
by Western blotting and RT-PCR from p19/ E16 embryos and
mouse embryonic fibroblasts (Fig. 1D and F). We then deter-
mined the expression of two genes neighboring the p19 locus, one
from each adjacent side (Fig. 1E). We found that mRNA expres-
sion of Kri1, a gene upstream of p19, and Ap1m2, a gene down-
stream of p19, was unchanged, whereas the expression of p19 was
undetectable in p19/ MEFs and embryos (Fig. 1F and data not
shown). These results further confirm that the targeting strategy
specifically disrupted the p19 gene without affecting the expres-
sion of its neighbor genes.
p19 mutant mice develop spontaneous tumors. The p19/
mice were produced in Mendelian ratios without significant de-
velopmental defects. The body weights of both male and female
p19/ mice were indistinguishable from those of WT mice (see
Fig. 4A). Though the testes of p19/ male mice were slightly
smaller than those of WT mice, p19-deficient males were fertile,
which is in agreement with previous findings (27, 28, 40). After
monitoring a cohort of 24 p19/, 9 p19/, and 15 wild-type
mice for 27 months, we found that 14 (58.3%) p19/ and 3
(30%) p19/ mice spontaneously developed tumors, whereas
only 2 (13.3%) WT mice displayed tumors at a similar age (Fig. 2A
and Table 1). The wide tumor spectrum of p19/ and p19/
mice included pituitary and lung adenomas, lymphomas, he-
mangiosarcoma, thyroid cancer, and insulinoma (Fig. 2B and E
and Table 1). Both p19/ and p19/ mice had a significantly
decreased tumor-free life span compared with WT controls
(P  0.0058 for WT versus p19/ and P  0.0219 for WT versus
p19/). The mean tumor-free survival times for p19/, p19/,
and WT mice were 640, 710, and 810 days, respectively (Fig. 2A).
In addition, p19 mutant mice were also predisposed to developing
pituitary and pancreatic islet hyperplasia as well as ovarian cysts
(Table 1). Taken together, these results reveal a function of p19 in
tumor suppression.
Loss of p19 leads to a hyperproliferative phenotype in pitu-
itary AL. Upon close examination of p19 mutant mice, we found
that, surprisingly, p19/ pituitaries, the AL in particular, were
larger than the WT organ at all ages after 3 months and that 30%
(3/9) of p19/ and 58% (14/24) of p19/ mice developed hy-
perplasia or adenoma in the pituitary (Fig. 2A and B, Fig. 3, and
Table 1) after 1 year of age. Nearly all pituitary hyperproliferative
phenotypes in p19 mutant mice were detected in the AL, unlike
those of p18 mutant mice, which are observed mostly in the IL
(15). We examined cell proliferation in p19/ pituitaries using
the proliferation marker Ki67. We found that there was increased
cell proliferation in p19/ pituitaries, particularly in the lesions
with hyperplasia or adenoma, compared to age-matched WT
FIG 2 p19 mutant mice develop spontaneous tumors. (A) Tumor-free sur-
vival curve of WT and p19 mutant mice. (B) Pituitaries from 1-year-old WT
and p19/ mice (top). A pituitary tumor from a 16-month-old p19/ mouse
was stained with H&E and is shown at low (bottom left) and high (bottom
right) magnifications. Note the tumor (T) in the anterior lobe. Mitotic cells
and blood lake in the tumor are indicated by the arrows and asterisk, respec-
tively. AL, anterior lobe; IL, intermediate lobe. (C) Representative immuno-
staining of pituitary anterior lobe tumors from p19/ mice with an antibody
against pRb-S608. Positive cells are indicated. (D) Kinase activity associated
with Cdk4 and Cdk6 in pituitaries of 1-year-old mice. Three pituitaries from
mice of each genotype were pooled for analysis. The results shown are the
means  SD of experiments in triplicate. Statistical significance was calculated
using Student’s t test. (E) Other representative tumors developed in p19/
mice.
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counterparts (5.1%  2.2% versus 1.6%  0.5% in 4-month-old
pituitaries [Fig. 3 and data not shown]). As determined micro-
scopically by their localization in the glands, the majority of the
proliferating cells in p19/ pituitaries were in the AL. We then
directly examined the status of Ser608 phosphorylation of Rb, the
site that is preferentially phosphorylated by the targets of p19,
CDK4, and CDK6 (46–48). A visible and consistent increase of
pRb-Ser608 phosphorylation was detected in normal p19/ pi-
tuitary ALs (6.9%  2.4% in p19/ versus 3.4%  1.5% in WT
[Fig. 3]) and in p19/ AL hyperplasias and adenomas (Fig. 2C),
supporting the activation of Cdk4 and/or Cdk6. These data are
also consistent with the previous finding that p19 is predomi-
nantly expressed in the AL of pituitary (40). We then determined
the kinase activity of Cdk4 and Cdk6 using GST-Rb as the sub-
strate. We found that Cdk4 and Cdk6 kinase activity increased 1.5-
and 1.3-fold in p19 null pituitaries in comparison with WT organs
(Fig. 2D), confirming the activation of Cdk4 and Cdk6 by p19 loss
in the pituitary. Finally, we performed immunohistochemistry
(IHC) and confirmed that there were proportionally greater num-
bers of prolactin (PRL)-, growth hormone (GH)-, and follicle-
stimulating hormone (FSH)-expressing cells in p19/ pituitaries
than in WT counterparts (PRL-positive cells, 23.1%  6.6% in
p19/ versus 16.3%  5.1% in WT; FSH-positive cells, 10.8% 
4.3% in p19/ versus 6.9%  2.8% in WT [Fig. 3 and data not
shown]). Taken together, these results demonstrate that p19 defi-
ciency stimulates Cdk4 and Cdk6 activity toward Rb protein in
pituitary AL cells, increasing their proliferation at an early age and
driving them from hyperplasia to tumor.
Cdk4 is not required for the development of a hyperprolif-
erative phenotype in p19/ pituitaries. The growth-suppressive
function of p19 in multiple tissues, particularly in the pituitary AL,
prompted us to determine whether the role of p19 in tumor sup-
pression, like that of p18, is dependent on Cdk4. To this end, we
generated p19 Cdk4 double mutant mice. At birth, WT, Cdk4/,
p19/, and p19/; Cdk4/ mice appeared indistinguishable
(data not shown). Soon after birth, however, various growth ab-
normalities were grossly apparent in Cdk4/ and p19/;
Cdk4/ mice. p19/ female mice were slightly bigger and
heavier than WT animals (Fig. 4A), and most p19/ mice lived
for up to 2 years, at which time they developed various tumors
(Table 1 and Fig. 2A). In contrast, most, if not all, Cdk4/ mice
died early in life (6 months) as previously reported (38, 49). Loss
of p19 had no significant effect on the postnatal mortality caused
by Cdk4 loss, and no p19/; Cdk4/ (n  22) (data not shown)
animal lived beyond 9 months. The body weights of Cdk4/ and
p19/; Cdk4/ mice were indistinguishable and lower than
those of WT or p19/ mice (Fig. 4A). Thus, loss of Cdk4 led to
growth retardation that was not rescued by p19 loss.
While Cdk4/ pituitaries in adult mice, as reported, were ex-
tremely hypoplastic (Fig. 3), p19/; Cdk4/ pituitaries were
slightly bigger than WT pituitaries at a similar age and were sig-
nificantly bigger than Cdk4/ counterparts (Fig. 3). p19/;
Cdk4/ pituitaries, AL in particular, displayed relatively normal
histology as observed in WT mice (Fig. 3), indicating that Cdk4 is
not required for pituitary development in p19 null mice and that
loss of p19 rescues AL hypoplasia induced by Cdk4 loss. Because of
early death of p19/; Cdk4/ mice from diabetes (see below),
we were unable to demonstrate that loss of Cdk4 would prevent
the development of pituitary hyperplasia and adenomas in older
p19/ mice.
To determine the cellular basis of functional independency of
p19 on Cdk4 in pituitary development, we performed IHC analysis
for pituitaries. In Cdk4/ pituitaries, Ki67-positive cells were
barely detectable in both the AL and IL (0.3%  0.1%), whereas
Ki67-positive cells were moderately increased in p19/; Cdk4/
pituitaries—particularly in the AL—relative to WT counterparts
(2.3%  0.8% in p19/; Cdk4/ versus 1.6%  0.5% in WT
mice [Fig. 3]). Consistently, we detected a significant decrease of
pRb-Ser608 phosphorylation in Cdk4/ pituitary AL (0.5% 
0.2%) and a drastic increase in p19/; Cdk4/ counterparts
compared with WT (7.3%  3.5% in p19/; Cdk4/ versus
3.4%  1.5% in WT mice [Fig. 3]). This result indicates that loss
of Cdk4 does not abolish the hyperproliferative phenotype in
p19/ pituitaries and loss of p19 rescues pituitary AL hypoplasia
caused by Cdk4 deficiency, suggesting that the development of a
hyperproliferative phenotype in p19/ pituitaries does not re-
quire Cdk4. Because Ser608 of Rb protein is preferentially phos-
phorylated by CDK4 and CDK6, the only two CDKs identified
thus far as downstream targets of p19 in the regulation of Rb, the
increase of pRb-Ser608 phosphorylation and proliferation in
p19/; Cdk4/ AL cells suggests that Rb phosphorylation in
Cdk4/ pituitaries, when p19 is lost, is likely through activation
of Cdk6. To corroborate this point, we then determined the ex-
pression of Cdk6 in the pituitary. We detected that Cdk6 was
predominantly expressed in AL cells and loss of either Cdk4 or
p19, or both, did not significantly affect the Cdk6 expression pat-
tern (Fig. 3). This result suggests an unidentified role of Cdk6 in
pituitary anterior lobe development.
TABLE 1 Pathology of p19 mutant mice
Organa and pathology
No. of mice displaying indicated clinical sign







AL 0 2 11
IL 0 0 3b
Adenoma
AL 0 1 3
IL 0 0 0
Lung
Hyperplasia 0 0 1
Adenoma 1 1 6
Pancreatic islet
Hyperplasia 0 1 4
Insulinoma 0 0 1
Ovary
Normal 5 6 8
Cyst 0 0 6
Other tumors
Lymphoma 1 1 3
Sarcoma 0 0 1
Thyroid tumor 0 0 1
No. of mice with tumor 2 3 14c
a IL, intermediate lobe; AL, anterior lobe.
b All three mice developed hyperplasia in both IL and AL.
c One mouse developed lung adenoma and lymphoma simultaneously.
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FIG 3 Characterization of pituitaries from mutant mice. Pituitaries from the indicated genotypes were stained with H&E, Ki67, pRb-S608, Cdk6, PRL, and FSH.
Insets show magnified representative cells. All pituitaries were derived from mice at 3 to 4 months of age, except one p19/ pituitary stained with Cdk6 that was
from a 16-month-old mouse showing the specific expression of Cdk6 in the AL of old mice. The percentages of Ki67-, pRb-S608-, PRL-, and FSH-positive cells
were calculated from 800 to 1,400 cells situated only in the AL. Results represent the means  SD of three animals per group. Statistical significance was calculated
using Student’s t test.
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To determine which particular cell lineage in pituitary AL was
affected by p19 or/and Cdk4 loss, we also performed IHC and
found that Cdk4/ pituitaries displayed markedly decreased
numbers of PRL- and GH-expressing cells with proportionally
increased numbers of FSH-expressing cells relative to WT (PRL-
positive cells, 3.8%  1.2% in Cdk4/ versus 16.3%  5.1% in
WT mice; FSH-positive cells, 30.9%  14% in Cdk4/ versus
6.9%  2.8% in WT mice [Fig. 3 and data not shown]), confirm-
ing hypoplasia of the lactotroph and somatotroph but not go-
nadotroph induced by Cdk4 loss (37, 50). Because a hypoplastic
lactotroph is responsible for the defective luteal function and fe-
male infertility of Cdk4 null mice and FSH plays an important role
in fertility of male mice, we then focused our study on PRL- and
FSH-expressing cells. We found that the numbers of PRL-express-
ing cells in p19/; Cdk4/ pituitaries were slightly greater than
in the WT but were significantly more than in Cdk4/ counter-
parts (PRL-positive cells, 18.3%  7.1% in p19/; Cdk4/ mice,
16.3%  5.1% in WT, and 3.8%  1.2% in Cdk4/ [Fig. 3]).
Interestingly, the number of FSH-expressing cells in p19/;
Cdk4/ pituitaries was less than in Cdk4/pituitaries but was
comparable with the number in WT counterparts (6.1%  2.5%
in p19/; Cdk4/, 6.9%  2.8% in WT, and 30.9%  14% in
Cdk4/ mice [Fig. 3]). These results indicate that p19-deficient
lactotrophs do not require Cdk4 for development and loss of p19
rescued hypoplasia of the lactotroph caused by Cdk4 deficiency.
Cdk4 is required for development of a hyperproliferative
phenotype in p19/ pancreatic islets. p19/ pancreatic islets
were bigger than WT counterparts at early ages, and p19/ mice
developed hyperplasia (4 of 24) and insulinoma (1 of 24) after 1
year of age, though p19/ mice displayed normoglycemia (Fig.
4B and C). In contrast, Cdk4/ mice developed diabetes with
hyperglycemia around 7 weeks of age, which was persistent
throughout their life, and the Cdk4/ pancreatic islets were sig-
nificantly smaller than the WT islets (Fig. 4) (21, 38, 49). Pancre-
atic phenotypes of p19/; Cdk4/ mice were very similar to
those of Cdk4/ mice: islets were sparsely located, and the num-
ber and size of islets were comparable to those of Cdk4/ mice
(Fig. 4B). Consistent with the defects in pancreatic islets, p19/;
Cdk4/ mice also developed diabetes with serum glucose levels
comparable to those of Cdk4/ mice (Fig. 4C). IHC revealed an
increase of Ki67-positive cells in p19/ islets and a significant
decrease of Ki67-positive cells in both p19/; Cdk4/ and
Cdk4/ counterparts (data not shown). These results indicate
that p19 suppresses pancreatic islet cell proliferation and loss of
p19 does not rescue defective islet cell proliferation caused by
Cdk4 loss. Instead, loss of Cdk4 abolishes the hyperplastic growth
of pancreatic islets caused by p19 deletion. These results suggest
that the function of p19 in islet proliferation, like that of p18 (21),
is also dependent on Cdk4.
Deletion of p19 rescues defective luteal function and infertil-
ity of Cdk4 null female mice. Pituitary lactotroph dysfunction is
responsible for the defective luteal function in Cdk4-deficient
mice (37, 50). Since deletion of p19 rescued hypoplasia of lac-
totroph caused by Cdk4 deficiency, we then speculated that p19
deficiency may also rescue Cdk4/ defective luteal function. To
test this hypothesis, we examined the ovaries of the mice. As pre-
viously reported (21, 38, 49) and also shown in Fig. 5A, adult
Cdk4/ ovaries at 4 months of age display very few corpora lutea
(CL)—at most one CL in each ovary. However, most ovaries from
WT, p19/, and p19/; Cdk4/ female mice formed one or
two CL in each ovary at a similar age, confirming that loss of p19
rescues lactotroph hypoplasia in Cdk4-deficient pituitaries, re-
sulting in normal luteal function.
The defective PRL production and luteal function caused by
hypoplasia of lactotroph are responsible for the infertility of fe-
male Cdk4 null mice (37, 50). Loss of p19 rescued Cdk4/ lac-
totroph hypoplasia and defective luteal function, suggesting that
p19/; Cdk4/ female mice may be fertile. To test the fertility of
the mutant mice, 10 p19/ female mice were mated for 21 days
with either WT or p19/ male mice separately. More than 60% of
FIG 4 Loss of p19 did not rescue the decreased body weight and diabetes of Cdk4-deficient mice. (A) Mean body weights from male and female mice of different
genotypes at 4 months of age were compared. Three to five mice from each genotype were weighed. SD bars are indicated. (B) H&E staining of pancreatic sections
from mice of different genotypes at 4 months of age. (C) Glucose levels in sera of 3- to 4-month-old mice were determined. Data were derived from three or four
mice from each genotype. SD bars are indicated. Statistical significance was calculated using Student’s t test.
p19Ink4d Is a Tumor Suppressor
June 2014 Volume 34 Number 12 mcb.asm.org 2127
p19/ female mice (6/10 mated with p19/ and 7/10 mated with
WT males) gave birth to an average of 6.5 and 7.8 pups within 21
days of males being introduced, respectively, which was slightly
but not significantly lower than what occurred with WT females
(90% pregnancy with an average of 9.2 pups [Table 2 and data not
shown]). No Cdk4/ female mice (0/10 mated with Cdk4/ and
0/10 mated with WT males) became pregnant, whereas 67% (4/6)
of p19/; Cdk4/ female mice mated with p19/; Cdk4/
males and 70% (7/10) of p19/; Cdk4/ female mice mated
with WT males became pregnant and gave birth to an average of
6.2 and 6.9 pups, respectively, in a similar mating course, which is
comparable to that of p19/ female mice (Table 2). Together,
these results confirmed that loss of p19 rescued the infertility of
Cdk4-deficient female mice.
Due to defective PRL production from the pituitary and pro-
gesterone secretion from the CL of the ovary, Cdk4/ female
mice are unable to support embryo implantation (37, 50). Both
PRL and progesterone are also essential for the proliferation and
differentiation of the developing mammary gland (51). Since de-
letion of p19 rescued lactotroph hypoplasia and defective luteal
function of Cdk4/ mice, we expected to detect normal mam-
mary development in p19/; Cdk4/ female mice. Indeed,
Cdk4/ mammary tissues, in line with the previous finding (52),
showed a distinctive reduction in the number of mammary ducts
with a significant decrease of mammary epithelial cell (MEC) prolif-
eration compared with WT counterparts, as evidenced by Ki67 stain-
ing (Fig. 5B and data not shown). As expected, there were more Ki67-
positive MECs in p19/ mice than in WT mice. p19/; Cdk4/
mice displayed amounts of Ki67-positive MECs comparable to
those of WT mice and significantly more Ki67-positive MECs
than Cdk4/ mice. These results suggest that the Cdk4 defi-
ciency-induced proliferation defect in MECs is rescued by
codeletion of p19, further confirming functional lactotrophs
and CL in p19/; Cdk4/ mice.
As a comparison, we also performed side-by-side analysis of
MEC proliferation in p18/ and p18/; Cdk4/ mice. We
FIG 5 Loss of p19 rescues defective luteal function and MEC proliferation as well as infertility of Cdk4-deficient mice. (A and B) Ovaries (A) and mammary
tissues (B) from mice of different genotypes at 4 months of age were stained with H&E and Ki67, respectively. The percentages of Ki67-positive cells were
calculated from cells situated in clear ductal/glandular structures. Results represent the means  SD of three animals per group. CL, corpus luteum. Statistical
significance was calculated using Student’s t test. (C) Testes from mice of different genotypes at 4 months of age were stained with H&E.








Female WT  male WT 9/10 9.2
Female p19/  male p19/ 6/10 6.5
Female p19/  male WT 7/10 7.8
Female WT  male p19/ 6/10 6.9
Female Cdk4/  male Cdk4/ 0/10 NAa
Female Cdk4/  male WT 0/10 NA
Female WT  male Cdk4/ 0/10 NA
Female p19/; Cdk4/  male p19/; Cdk4/ 4/6 6.2
Female p19/; Cdk4/  male WT 7/10 6.9
Female WT  male p19/; Cdk4/ 3/5 6.3
a NA, not applicable.
Bai et al.
2128 mcb.asm.org Molecular and Cellular Biology
found that Ki67-positive MECs in p18/; Cdk4/ mice were
indistinguishable from those of Cdk4/ mice, though a robust
increase of Ki67-positive MECs was detected in p18 null mice
compared to WT (Fig. 5B), indicating that the function of p18 in
suppressing MEC proliferation, unlike that of p19, is dependent
on Cdk4. This result is in agreement with our previous finding that
loss of p18 does not rescue pituitary hypoplasia and lactotroph
dysfunction or the defective luteal function in Cdk4-deficient
mice (21), which are the direct causes of female infertility and
hypoproliferative MECs in p18/; Cdk4/ mice.
Taken together, these results indicate that Cdk4 is not required
for female fertility or development of the ovaries and mammary
glands in p19-deficient mice. Codeletion of p19 in Cdk4-deficient
mice rescued lactotroph hypoplasia, resulting in normal luteal
function, leading to female fertility with normal mammary gland
development.
Deletion of p19 rescues the infertility of Cdk4 null male mice.
All Cdk4/ male mice tested failed to induce female pregnancy,
and 60% of p19/ male mice induced female pregnancy (6/10
mated with p19/ and 6/10 mated with WT females), which was
slightly but not significantly lower than for WT males (70% mated
with p19/ and 90% mated with WT females [Table 2]). Impor-
tantly, 60% to 67% of p19/; Cdk4/ male mice were able to
induce female pregnancy (3/5 mated with WT and 4/6 mated with
p19/; Cdk4/ females [Table 2]). Histology analysis revealed
that while Cdk4/ testes contained abnormal seminiferous tu-
bules with degeneration of a significant fraction of primary sper-
matocytes and very few normal spermatozoa at an age of 4
months, testes from p19/ and p19/; Cdk4/ mice displayed
relatively normal seminiferous tubules compared with WT mice
(Fig. 5C). These results suggest that deletion of p19 rescues testic-
ular atrophy and infertility of male mice lacking Cdk4. It remains
to be determined whether the rescue of hypoplasia in Cdk4/
pituitaries by p19 loss contributes to the rescue of infertility of
Cdk4/ males, since we did not detect proliferation defects in
FSH-expressing cells in Cdk4/ and p19/; Cdk4/ pituitaries.
Loss of p19 increases kinase activity of Cdk4 and Cdk6, accel-
erating cell proliferation. Early-passage primary p19/ MEFs
proliferated faster than WT MEFs from the same litter at different
passages (Fig. 6A). Consistently, BrdU pulse-labeling and flow
cytometric analysis of asynchronously growing MEFs indicated
that the p19/ MEFs had decreased G1- and increased S-phase
cells relative to their WT counterparts (S-phase cells, 29.3% 
3.2% versus 22.3%  2.1% [Fig. 6B]). Analysis of Rb protein in
MEFs indicated that the level of total protein was reduced but the
slower-migrating, hyperphosphorylated form was increased in
p19/ MEFs (Fig. 6C). Consistently, kinase activities of Cdk4 and
Cdk6, the latter in particular, were enhanced in p19/ MEFs
compared to their WT counterparts (1.3-fold for Cdk4 and 2.0-
fold for Cdk6 [Fig. 6D]), confirming the activation of Cdk4 and
Cdk6 by p19 deficiency in MEFs. To test whether reduction of Rb
protein was specifically caused by p19 loss and not due to second-
ary effects, we targeted p19 mRNA in WT MEFs by RNA interfer-
ence (RNAi). An effective suppression of p19 in MEFs was
achieved as determined by both RT-PCR and immunoblotting
(Fig. 6E and data not shown). The level of pRb protein in siRNA-
targeted WT MEFs was also reduced, although not as much as in
p19/ MEFs (Fig. 6C and E). Transduction of p19 (Fig. 6F) and
p16 (data not shown) retroviruses into p19/ MEFs nearly com-
pletely inhibited DNA synthesis, indicating that p19/ MEFs re-
tained intact Rb and p107–p130 functions. The role of p19 in the
negative regulation of S phase was consistent with its oscillating
expression during the cell cycle: there was an accumulation of p19
in serum-deprived quiescent cells, which then fell sharply during
G1 after serum stimulation and accumulated again as cells pro-
gressed through the S phase (Fig. 6G). To further determine the
function of p19 in the G1-to-S transition, we examined the re-
sponse of p19/ MEFs to serum starvation. Compared to WT
MEFs, deletion of p19 resulted in an accelerated progression
through the G1 phase and entry into S phase. While 15% and 25%
of p19/ MEFs had started DNA replication at 18 and 24 h post-
serum stimulation, respectively, only 7% and 15% of WT MEFs
were BrdU positive (Fig. 6H and I) at the same time points. To-
gether, these results indicate that loss of p19 function increases the
kinase activity of Cdk4 and Cdk6, particularly that of Cdk6, accel-
erating the G1-to-S transition.
Loss of p19 increases Cdk6 activity, rescuing S-phase delay in
MEFs lacking Cdk4. The cell cycle kinetics of p19/ MEFs in
response to serum deprivation-stimulation was in contrast to that
of Cdk4/ MEFs, which as previously reported displayed a de-
layed entry into S phase relative to WT MEFs, but it was similar to
that of p18/ MEFs, which also displayed accelerated progres-
sion through the G1 phase (21, 38, 49). To determine the func-
tional interaction between CDK4 and p19, we generated p19/;
Cdk4/ MEFs and determined their cell cycle kinetics in re-
sponse to serum deprivation and stimulation. We found that
p19/; Cdk4/ MEFs exhibited kinetics more similar to those of
WT MEFs: 4% and 13% of cells were stained positive for BrdU at
18 and 24 h post-serum stimulation, respectively, which is signif-
icantly higher than for Cdk4/ MEFs, where 1% and 7% of cells
were BrdU positive at the same time points (Fig. 6H and I). These
results indicate that p19 plays a critical role in controlling the
serum response in MEFs by regulating not only Cdk4 but also
another target—likely Cdk6 —and that a delay in S-phase entry by
loss of Cdk4 could be compensated by an increase of Cdk6 activity.
These data are consistent with the findings derived in vivo indicat-
ing that loss of p19 rescues the hypoproliferative phenotypes as-
sociated with Cdk4 deficiency in the lactotroph.
Next, we determined Cdk6 activity using the ADP-Glo kinase
assay kit and found that p19/; Cdk4/ MEFs displayed 1.3-fold
more Cdk6 kinase activity than Cdk4/ MEFs (Fig. 6J). To fur-
ther consolidate the role of p19 in the regulation of kinase activity
of Cdk4 and Cdk6, we developed a new assay. We immunopre-
cipitated Cdk4- and Cdk6-associated complexes from mouse thy-
mus, which express high levels of both Cdk4 and Cdk6 (data not
shown), and incubated the complex with a GST-Rb substrate in
the presence of ATP. The reaction was terminated, and the results
were analyzed by Western blotting with a phosphothreonine-spe-
cific antibody (P-Thr). We detected strong phosphorylated Rb
bands induced by Cdk4- and Cdk6-associated complexes and a
very faint band in the IgG control (Fig. 6K), validating this assay as
an alternative means to determine Cdk4 and Cdk6 activity in vitro.
We then immunoprecipitated Cdk4- and Cdk6-associated com-
plexes from MEFs of different genotypes and detected greater
phosphorylation of Rb in p19/ MEFs than in WT fibroblasts
(Fig. 6L, lanes 2 and 6 versus lanes 1 and 5, respectively). Com-
pared to WT, the increased Cdk6-associated phosphorylation of
Rb in p19/ MEFs is more drastic than the Cdk4-associated
phosphorylation of Rb. These results further confirm the en-
hancement of kinase activity of Cdk4 and Cdk6, particularly that
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FIG 6 p19 controls proliferation of MEFs that is not dependent on Cdk4. (A) A total of 106 primary WT and p19/ MEFs isolated from two separate litters were
cultured on 100-mm dishes in duplicate on a 3T9 protocol for 7 passages. At 3-day intervals, the number of cells on each plate was determined prior to reseeding
106 cells per dish for the next passage. (B) Asynchronously growing MEFs derived from the littermate embryos at passage 1 were pulse-labeled with BrdU. Cells
were stained with anti-BrdU antibody and propididum iodide (PI) and then analyzed by flow cytometry. The percentages of BrdU-positive (S-phase), G1, and
G2 cells are shown. The average percentages of BrdU-positive cells were calculated from three different pairs of MEFs. (C) Asynchronously growing MEFs at early
passages were collected and lysed, and the expression of pRb was examined by Western blotting. (D) Kinase activity associated with Cdk4 and Cdk6 in MEFs of
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of Cdk6, by p19 loss in MEFs. Importantly, the Cdk6-associated
Rb phosphorylation in p19/; Cdk4/ MEFs is significantly in-
creased compared to Cdk4/ MEFs (Fig. 6L, lane 8 versus lane 7),
further confirming the increase of Cdk6 activity in p19/;
Cdk4/ MEFs relative to Cdk4/ MEFs. Consistent with these
data, we detected more cyclin D coimmunoprecipitated with
Cdk6 in p19/; Cdk4/ MEFs than in Cdk4/ MEFs, though
Cdk6 levels were comparable in these cells (Fig. 6M, lane 3 versus
lane 4), indicating that loss of p19 stimulates binding of cyclin D to
Cdk6 in Cdk4-deficient cells. Interestingly, we repeatedly detected
more cyclin D in p19/; Cdk4/ MEFs than in Cdk4/ MEFs
(Fig. 6M, lanes 1 and 2), suggesting that loss of p19 in Cdk4-
deficient MEFs also resulted in the increase of cyclin D protein
level, the mechanism of which remains to be determined. We then
transfected Cdk6 in Cdk4/ MEFs and found that ectopic Cdk6
stimulated phosphorylation of Rb protein (Fig. 6N, left panel) and
increased BrdU incorporation compared with control MEFs
(6.9% versus 2.3% [Fig. 6N]). Furthermore, BrdU incorporation
in Cdk4/ MEFs overexpressing Cdk6 was comparable with that
in p19/; Cdk4/ MEFs (6.9% versus 7.4% [Fig. 6N]), indicat-
ing that overexpression of Cdk6 is sufficient to drive Cdk4/
MEFs into S phase with faster kinetics.
In sum, these results suggest that loss of p19 increases the ki-
nase activity of Cdk6 by stimulating its binding with cyclin D,
leading to rescue of S-phase delay in MEFs deficient for Cdk4.
DISCUSSION
p19 functions as a tumor suppressor. Mice lacking p19 devel-
oped widespread hyperplasia and spontaneous tumors, indicating
a role of p19 in tumor suppression. Consistent with its broad
expression (24), tumors spontaneously developed in p19 mutant
mice across a wide spectrum of at least 6 different organs or tis-
sues. The mechanism underlying the tumor development induced
by p19 loss is that loss of p19 function, like that of the other three
members of Ink4 family cell cycle inhibitors, enhances the activity
of Cdk4/6 and phosphorylation of Rb protein, leading to signifi-
cantly increased cell proliferation and eventually tumor develop-
ment.
Of the four Ink4 family members, p19 is the most highly and
ubiquitously expressed in embryos and adult tissues (24). Bio-
chemical properties of the individual INK4 members are almost
indistinguishable (1, 2). However, loss of p15 confers proliferative
advantage to MEFs and results in a moderate increase of tumor
development, mostly sarcomas, in mice (11). p16 null mice de-
velop sarcomas, lymphomas, and melanomas (10, 12), and p18
null mice develop widespread hyperplasia, organomegaly, and
breast and pituitary IL tumors (11, 15). Our finding that deletion
of p19 in mice leads to widespread tumor development is in agree-
ment with the observation that loss of p19 expression is frequently
detected in human cancers (25, 26). The broad and distinct ex-
pression patterns of INK4 members as well as diverse phenotypes
of the mice lacking individual Ink4 genes further support a model
that INK4 genes collaboratively suppress tumor development in
vivo.
Previous analyses of mice harboring a different mutant p19
allele, p19tm1Maro, containing an insertion of LacZ-Neor, demon-
strated a relatively minor phenotype of testicular atrophy and no
tumor phenotype (28). The discrepant results from two different
mutant p19 alleles are likely caused by the use of mice with differ-
ent genetic backgrounds as well as different targeting strategies, in
which we deleted the entire p19 gene from the genome without
insertion of exogenous genes. Four lines of evidence collectively
support that the tumorigenic and cellular phenotypes described in
our study are caused by the loss of p19 function. First, all hyper-
plastic and tumorigenic phenotypes observed in our p19 null mice
have been previously described in mice that lack individual or a
combination of Rb genes or harbor an Ink4-resistant mutation of
Cdk4 (2, 4–7, 39, 53, 54). Second, the pattern of p19 gene expres-
sion is consistent with the phenotypes observed in null MEFs:
accelerated G1-to-S transition. In cultured cells, the levels of p19
mRNA and protein oscillate during the cell cycle, accumulating in
quiescent cells, falling sharply during G1 phase, and accumulating
again as cells progress through the S phase (Fig. 6 and reference
55). Third, p19 null MEFs and cells in multiple organs are highly
proliferative, with a concomitant increase of Cdk4/6 activity and
Rb protein phosphorylation at a Cdk4/6-specific site, consistent
with the notion that INK4 genes function as upstream activators
of Rb protein through the inhibition of Cdk4/6. Fourth, knock-
down of p19 in WT MEFs, like p19/ MEFs, also led to a de-
creased level of Rb protein (Fig. 6E), and that transduction of WT
different genotypes. Results represent the means  SD from triplicates of representative MEFs generated from littermate embryos. (E) WT MEFs at passage 1
were transfected with either single-stranded sense RNA oligonucleotides or siRNA duplex targeting p19. The expression of p19 and Rb was determined by
Western analysis. (F) p19/ MEFs were infected with a retrovirus expressing p19 or empty vector. Forty-eight hours after infection, cells were pulse-labeled with
BrdU for 4 h and analyzed by flow cytometry. p19 expression was verified by Western blotting of total cell lysates prepared 24 h and 48 h after infection. (G) WT
MEFs were serum deprived for 3 days and released from quiescence by serum stimulation. Total RNA was prepared from cells at different time points after serum
stimulation as well as from an asynchronized cell population as indicated. RNA samples were resolved on a 1% agarose gel, transferred to a nitrocellulose filter,
and hybridized with a probe derived from full-length mouse p19 cDNA. The blot was then stripped and rehybridized with a mouse GAPDH probe. The amount
of p19 mRNA at each time point of the Northern blot was normalized by GAPDH and plotted (bottom panel). (H) MEFs of different genotypes were starved for
72 h (time zero), followed by stimulation of cells with medium containing 10% serum. Cells were pulse-labeled with BrdU and harvested at the times indicated
after stimulation. Cells were stained with anti-BrdU antibody and PI and then analyzed by flow cytometry. BrdU-positive cells are marked by a box. (I) The
percentage of cells in S phase from each time point in panel H was plotted. Results represent one of three independent experiments from three independent
p19/; Cdk4/ and Cdk4/ MEFs and two independent WT and p19/ MEFs. (J) Kinase activity associated with Cdk6 in MEFs of different genotypes.
Results represent the means  SD from triplicates of representative MEFs generated from littermate embryos. (K) Lysate from 6-week-old mouse thymus was
precipitated with antibodies against Cdk4 and Cdk6 or with rabbit IgG and buffer as negative controls. Immunoprecipitates were reacted with GST-Rb in the
presence of ATP, separated electrophoretically, and immunoblotted with a phosphothreonine-specific antibody. Phosphorylated Rb (P-Rb) and Ponceau-
stained GST-Rb are shown. (L) Lysates from MEFs of different genotypes were precipitated with antibodies against Cdk4 or Cdk6. Immunoprecipitates were
reacted with GST-Rb in the presence of ATP and immunoblotted with a phosphothreonine-specific antibody. (M) Lysates from MEFs of different genotypes were
precipitated with antibodies against Cdk6 or rabbit IgG. Immunoprecipitates were immunoblotted with antibodies against Cdk6 or Cyc D (mixture of Cyc D1,
D2, and D3). (N) Cdk4/ MEFs at passage 4 were transfected with pCMV-Cdk6 (Cdk6) or pCMV-empty (Ctrl) for 2 days, and the cells were lysed for Western
blotting (left panel) or pulse-labeled with BrdU for flow cytometry analysis with anti-BrdU antibody and PI (right panel). BrdU-positive cells are marked by a
box. p19/; Cdk4/ MEFs at passage 4 transfected with pCMV-empty (Ctrl.) in parallel were also analyzed by flow cytometry as a control.
p19Ink4d Is a Tumor Suppressor
June 2014 Volume 34 Number 12 mcb.asm.org 2131
p19 in p19/ MEFs nearly completely inhibited DNA synthesis
(Fig. 6F).
To address the possibility that the expression of a gene(s)
closely linked to p19 was inadvertently affected in our mutant
mice, we determined the mRNA levels of two genes neighboring
the p19 locus, one from each adjacent side, by qRT-PCR. No dis-
cernible change of mRNA level was seen in any of these genes.
While we cannot exclude the possibility that one of these p19
neighboring genes endured a subtle change in spatial or tempo-
rary expression beyond our detection sensitivity or that the ex-
pression of a gene at a greater distance from the p19 locus might
have been inadvertently affected in our mutant, we consider the
probability of such an event occurring, and thus contributing to
the observed phenotype, to be exceedingly low.
Function of p19 in controlling pituitary AL cell proliferation.
In this paper, we provide compelling genetic evidence that p19
plays a critical role in suppressing pituitary AL cell proliferation.
We discovered that deletion of p19 in mice stimulates Cdk4 and
Cdk6 activity toward Rb protein in pituitary AL cells, increasing
their proliferation, particularly of lactotrophs, at an early age and
eventually leading to hyperplasia and spontaneous tumor devel-
opment. Loss of p19 rescues pituitary AL hypoplasia caused by
Cdk4 deficiency, and loss of Cdk4 does not abolish the hyperpro-
liferative phenotype in p19/ pituitaries, suggesting that devel-
opment of a hyperproliferative phenotype in p19/ pituitaries
does not require Cdk4. We demonstrated that loss of p19 leads to
phosphorylation of Rb in Cdk4/ pituitary AL cells, likely
through the activation of Cdk6. These results, together with pre-
vious findings derived from p15, p16, p18, p21, p27, and p57 mu-
tant mice (8–17), suggest that p19 is the major CKI gene that
controls pituitary AL cell proliferation.
Most pituitary hormones are produced in the AL, and most
human pituitary tumors are AL tumors that express and secrete
several hormones that contribute to various endocrine syndromes
(34). In this study, we show that loss of Cdk4 alone, as reported
(37, 38), does not induce a compensatory increase of Cdk6 in the
pituitary, leading to defective cell proliferation. However, Cdk6
plays a significant role in regulating p19/; Cdk4/ cell prolif-
eration in the pituitary AL, either in its own right or induced in a
compensatory manner after Cdk4 loss, thereby sensitizing cells to
p19 loss. Consistent with these findings were the observations that
both p19 and Cdk6 are predominantly expressed in pituitary AL
and that deletion of p19 increases Cdk6 activity in the pituitary
(Fig. 2D and 3 and reference 40). Nearly all Cdk4/ mice died of
diabetes early in life, with tiny pituitaries (Fig. 3 and 4), which
prevented us from obtaining enough pituitaries from Cdk4/
mice to directly confirm the increase of Cdk6 activity in p19/;
Cdk4/ pituitaries in comparison to Cdk4/ pituitaries. Nota-
bly, Cdk6 is readily detectable in MEFs (38), like in pituitary AL
cells, and the loss of p19 significantly increases the kinase activity
of Cdk6 as well as rescues the delay of G1-to-S progression of
Cdk4/ MEFs following serum deprivation and stimulation (Fig.
6H, I, J, and L)—the key cellular defect caused by Cdk4 loss—
supporting the role of Cdk6 in controlling G1 progression of
p19/; Cdk4/ cells. The findings that loss of p19 stimulates
binding of cyclin D to Cdk6 in Cdk4-deficient MEFs and that
ectopic expression of Cdk6 is sufficient to drive Cdk4/ cells into
S phase with faster kinetics further confirm that in the absence of
Cdk4, p19 contributes to the failure of cells to enter S phase by
preventing Cdk6 activation. Still, the in vivo function of Cdk6
systemically in the whole body and the manner in which Cdk6
compensates Cdk4 loss in different cell types and tissues remain
unclear. However, the findings that Cdk6 is expressed at a very low
level and does not compensate for Cdk4 loss in the pancreas (38)
and that Cdk4 loss cancels the pancreatic islet phenotype caused
by p19 loss but does not affect p19 deficiency defects in the pitu-
itary suggest that Cdk6 plays an important role in vivo in mediat-
ing the function of p19 in a tissue-specific manner.
Defective PRL production in the Cdk4/ pituitary AL is the
cause of CL defects that then lead to defective progesterone secre-
tion and female infertility (37, 50). We found that p19/;
Cdk4/, but not p18/; Cdk4/, female mice are fertile with
hyperproliferative lactotrophs as well as normal ovary CL forma-
tion and MEC proliferation (this study and reference 21), indicat-
ing that loss of p19 but not p18 in Cdk4/ mice rescues lac-
totroph hypoplasia, resulting in normal luteal function and
leading to female fertility with normal MEC proliferation. These
results not only suggest a functional dependency of p18 and inde-
pendency of p19 on Cdk4 in controlling pituitary cell proliferation
but also confirm that lactotroph dysfunction is responsible for
Cdk4-deficient female infertility and defective MEC proliferation.
Most, if not all, Cdk4/ male mice are sterile, with impaired
spermatogenesis (38, 49), which is also rescued by loss of p19 but
not by loss of p18 (21). Due to the extremely low levels of Cdk6
protein expressed in WT testes (18, 38), it is unlikely that Cdk6
plays a critical role in regulating spermatogenesis of p19/;
Cdk4/ mice. Diabetes-associated sterility has been documented
in diabetic patients and animals (56, 57), and sterility of Cdk4/
male mice may also be caused by their diabetic phenotype (49).
However, our results that p19/; Cdk4/ male mice are fertile
but also develop diabetes and that p18/; Cdk4/ mice are ster-
ile and have diabetes (21) suggest that male sterility in Cdk4/
mice is not a result of diabetes but is very likely—at least partial-
ly— caused by pituitary hypoplasia. How pituitary hypoplasia in
Cdk4/ male mice induces their sterility remains to be deter-
mined.
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